Tal Burt

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2016-2022
Publications (10 Years): 3

Top Topics

Top Venues

Nature reviews. Drug discovery

Clinical and translational science

Journal of Korean medical science

Burt Consultancy, LLC.

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Burt Consultancy, LLC. Jan 01 2015

United States

President/CEO

Phase-0/Microdosing Network Jul 01 2012

United States

President/CEO

Duke University Mar 01 2010 - Jun 30 2015

United States

Scientific Director :: Duke Clinical Research Institute

Duke-NUS Graduate Medical School Aug 01 2008 - Dec 31 2009

Singapore

Associate Professor of Clinical Research :: Clinical Research

Eisai Inc Jun 01 2006 - Aug 01 2007

United States

Senior Medical Director :: Early-Phase Clinical Research

Pfizer Inc Jul 01 2000 - Mar 01 2006

United States

Senior Medical Director :: Clinical Research

Publications

Tal Burt, Ad F Roffel, Oliver Langer, Kirsten Anderson, Joseph A DiMasi
Strategic, feasibility, economic, and cultural aspects of phase 0 approaches: Is it time to change the drug development process in order to increase productivity? Clinical and translational science 15 (6) (2022)
Tal Burt, Graeme C Young, Wooin Lee, Hiroyuki Kusuhara, Oliver Langer, Malcolm Rowland, Yuichi Sugiyama
Phase 0/microdosing approaches: time for mainstream application in drug development? Nature reviews. Drug discovery 19 (11) (2020)
Yun Jung Choi, Sung-Ho Beck, Woon Yong Kang, Soyoung Yoo, Seong-Yoon Kim, Ji Sung Lee, Tal Burt, Tae Won Kim
Knowledge and Perception about Clinical Research Shapes Behavior: Face to Face Survey in Korean General Public. Journal of Korean medical science 31 (5) (2016)